|
Volumn 15, Issue S1, 2014, Pages 6-7
|
Personalised medicine in cystic fibrosis must be made affordable
|
Author keywords
Cystic Fibrosis; Personalised Medicine
|
Indexed keywords
ANTIBIOTIC AGENT;
ASPARTIC ACID;
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;
GLYCINE;
IVACAFTOR;
AFFORDABILITY;
ARTICLE;
BUDGET;
CLINICAL RESEARCH;
CONFIDENTIALITY;
COST EFFECTIVENESS ANALYSIS;
CROSS INFECTION;
CYSTIC FIBROSIS;
DISEASE EXACERBATION;
DISEASE REGISTRY;
DRUG APPROVAL;
DRUG COST;
DRUG EFFICACY;
EVIDENCE BASED MEDICINE;
FINANCIAL MANAGEMENT;
FORCED EXPIRATORY VOLUME;
FUNDING;
GENE MUTATION;
HEALTH CARE;
HEALTH CARE ACCESS;
HEALTH CARE COST;
HEALTH CARE DELIVERY;
HEALTH CARE PLANNING;
HEALTH CARE QUALITY;
HEALTH CARE SYSTEM;
HEALTH INSURANCE;
HEALTH SERVICE;
HOME CARE;
HUMAN;
INFECTION RISK;
ION TRANSPORT;
LUNG CLEARANCE;
LUNG INFECTION;
MEDICAL SPECIALIST;
NEBULIZATION;
PATIENT ATTITUDE;
PATIENT CARE;
PATIENT MONITORING;
PERSONALIZED MEDICINE;
PRIORITY JOURNAL;
TABLET;
TEAMWORK;
ADULT;
CHILD;
COST;
ECONOMICS;
ADULT;
CHILD;
COSTS AND COST ANALYSIS;
CYSTIC FIBROSIS;
HUMANS;
INDIVIDUALIZED MEDICINE;
|
EID: 84901589330
PISSN: 15260542
EISSN: 15260550
Source Type: Journal
DOI: 10.1016/j.prrv.2014.04.004 Document Type: Article |
Times cited : (6)
|
References (4)
|